On November 4, Xinkang® Lacosamide injection, declared by Jiangxi Qingfeng Pharmaceutical Co., Ltd., was approved by NMPA and deemed to have passed the consistency evaluation. This is the first generic market in China, the third-generation anti-epileptic injection product. Xinkang® Lacosamide injection is another new member of the family one year after Xinkang® Lacosamide tablets were marketed.